Cantor Fitzgerald Lowers Price Target on Nektar (NKTR) to $21
Tweet Send to a Friend
Cantor Fitzgerald maintains a 'Buy' rating but reduces the price targe ton Nektar Therpeutics (Nasdaq: NKTR) from $23 to $21 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
